{"id":541195,"date":"2026-07-09T15:30:10","date_gmt":"2026-07-09T15:30:10","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/541195\/"},"modified":"2026-07-09T15:30:10","modified_gmt":"2026-07-09T15:30:10","slug":"long-term-follow-up-of-postoperative-chemoradiotherapy-with-3-weekly-vs-weekly-cisplatin-in-head-and-neck-cancer","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/541195\/","title":{"rendered":"Long-Term Follow-up of Postoperative Chemoradiotherapy With 3-Weekly vs Weekly Cisplatin in Head and Neck Cancer"},"content":{"rendered":"<p>&#13;<br \/>\n    \t\t  <a href=\"https:\/\/www.ascopost.com\/search-results\/?q=Matthew+Stenger\" rel=\"nofollow noopener\" target=\"_blank\">By Matthew Stenger<\/a><br \/>&#13;<br \/>\n\t\t  <a href=\"https:\/\/ascopost.com\/news\/july-2026\/\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>&#13;<br \/>\n\t\t  &#13;<br \/>\n\t\t  Posted: 7\/9\/2026 10:09:00 AM&#13;<br \/>\n\t\t  <br \/>&#13;<br \/>\n           Last Updated: 7\/9\/2026 10:16:42 AM&#13;<br \/>\n\t\t  &#13;\n\t\t<\/p>\n<p>&#13;<\/p>\n<p>In the long-term follow-up of a Japanese phase II\/III trial (JCOG1008) reported in the <a href=\"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-01708\" rel=\"nofollow noopener\" target=\"_blank\">Journal of Clinical Oncology<\/a>, Tahara et al found maintained noninferiority of chemoradiotherapy with weekly vs every-3-week cisplatin for overall survival in patients with postoperative high-risk locally advanced squamous cell carcinoma of the head and neck.<\/p>\n<p>Study Details<\/p>\n<p>In the multicenter trial, 261 patients were randomly assigned to receive chemoradiotherapy with cisplatin at 40 mg\/m2 once weekly for seven cycles (n = 129) or cisplatin at 100 mg\/m2 once every 3 weeks for three cycles (n = 132). An interim analysis showed that chemoradiotherapy with weekly cisplatin was noninferior in overall survival compared with chemoradiotherapy with 3-weekly cisplatin.<\/p>\n<p>Key Findings<\/p>\n<p>At final analysis, with a median follow-up of 5.6 years, 5-year overall survival was 58.7% in the 3-weekly group and 71.2% in the weekly group (hazard ratio [HR] = 0.76, 95% confidence interval [CI] = 0.52\u20131.12 [&lt;1.32 noninferiority threshold]), confirming noninferiority of the weekly regimen.<\/p>\n<p>Five-year relapse-free survival was 53.0% in the 3-weekly group vs 64.3% in the weekly group (HR = 0.81, 95% CI = 0.57\u20131.16). Five-year local relapse-free survival was 57.2% vs 68.8% (HR = 0.79, 95% CI = 0.54\u20131.14).<\/p>\n<p>No late adverse events of any grade showed more than a 10% difference between the two groups.<\/p>\n<p>The investigators stated: \u201cIn conclusion, 5-year follow-up confirmed that chemoradiotherapy with weekly cisplatin is noninferior in [overall survival] to chemoradiotherapy with 3-weekly cisplatin in patients with postoperative high-risk [locally advanced squamous cell carcinoma of the head and neck]. These results further support the use of weekly cisplatin plus radiotherapy as a reasonable alternative for this patient population.\u201d<\/p>\n<p>Makoto Tahara, MD, PhD, of National Cancer Center Hospital East, Kashiwa, Japan, is the corresponding author for the Journal of Clinical Oncology article.<\/p>\n<p>DISCLOSURE: The study was supported by the National Cancer Center Research and Development Fund and others. For full disclosures of the study authors, visit <a href=\"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-01708\" rel=\"nofollow noopener\" target=\"_blank\">ascopubs.org<\/a>.<\/p>\n<p>&#13;<\/p>\n","protected":false},"excerpt":{"rendered":"&#13; By Matthew Stenger&#13; &#13; &#13; Posted: 7\/9\/2026 10:09:00 AM&#13; &#13; Last Updated: 7\/9\/2026 10:16:42 AM&#13; &#13; &#13;&hellip;\n","protected":false},"author":2,"featured_media":541196,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[103,61,60],"class_list":["post-541195","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-ie","tag-ireland"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/541195","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=541195"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/541195\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/541196"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=541195"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=541195"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=541195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}